

## JAN 2 1 2004 TC 1700

P&G Case CM1956Q

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas Wolfgang Friedrich Hirn et al.

Serial No.: 09/831,610

Filed: May 10, 2001

Confirmation No.: 5738

Group Art Unit: 1772

Examiner: Edward J. Cain

A FILM WITH UV-BARRIER PROPERTIES For:

INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patents** P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

#### 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional 1. patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

#### 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a 2. nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required

RECEIVED MAR 24 2004 TC 1700

fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

## 3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 4. [X] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] <u>Information to be Considered with Continued Prosecution Application</u> (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for <u>Design Case</u>). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

#### ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

[] (2) (For use with applications filed after June 30, 2003.) In accordance with 3	37
C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and no	n-
patent literature.	
OR	
(3) All of the cited references were previously cited by or submitted to the USPTO	in
prior application Case No, U.S. Patent Application Serial No, filed Applican	ts
claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previous	ly
submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It	
respectfully requested that the cited documents be carefully considered by the Examiner ar	ıd
made of record in this case.	
OR	
[] (4) Copies of all said documents, except Cite Numbers, were submitted	
and considered in parent application U.S. Patent Application Serial No, file	
. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly	, ,
copies of previously submitted references are not provided with this Statement, pursuant to 3 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfull	
requested that the cited documents be carefully considered by the Examiner and made of recor	•
in this case.	Ų.
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cite	d
reference that is not in the English language is provided.	
[] (6) Applicants also respectfully request the Examiner to consider and make of recor	d
the co-pending applications listed on the attached page.	
Additional information is attached.	
Respectfully submitted,	
FOR: Thomas Wolfgang Friedrich Hirn et al.	
By: Stephen T. Murphy	
Date: January 13, 2004 Attorney for Applicant(s)	
Customer No. 27752 Registration No. 42,917 (IDS.doc) (Last Revised 10/10/03) (513) 634-4268	
(313) (317) (317)	

### RECEIVED

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

JAN 2 1 2004 Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

<b>700</b> COMPI	LETE IF KNOWN
Application Number	09/831,610
Confirmation Number	5738
Filing Date	May 10, 2001
First Named Inventor	Thomas W. F. Hirn et al.
Group Art Unit	1772
Examiner Name	Edward J. Cain
Attorney Docket Number	CM1956Q

#### **U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	U.S. PATENT DOCUMENT Number Kind Code <sup>2</sup> (if known)		Kind Code <sup>2</sup> Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
						RECE	
						MAR	
						TO 14 2004	
						1700	

#### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
		EP	0768277	-	A1	Nippon Shokubai Kagaku Kogyo Co. LTD.	04-16-1997		
		WO	98/06575			Imperial Chemical Industries	02-19-1998		-
<del></del> ,									

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
EXAMINER		DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.